MBX Capital — 2025 Investments
3 investments dated 2025 · listed companies and verified rows first · show all
Enoda develops synthetic cytokine receptors, called MIMICs, that link therapeutic "Signal 3" cytokine functions to controllable inputs to engineer cell therapies without systemic toxicity.
BiotechDeep TechLondon
Andrew John Scobie(Executive Officer, Director)Michael Chavez(Co-founder & CEO)Paul Finn(Co-founder & CTO)Paul B. Finn(Founder)inJennifer Urquhart(Executive Officer, Director)Jacqueline Elizabeth Porch(Executive Officer, Director)
Co-investorsFifty Years
Juniper Genomics provides genomic testing for IVF, including enhanced PGT-A that analyzes both DNA and RNA from a single embryo biopsy to assess chromosome status and embryo viability, and PGT-G that expands analysis across nearly the full genome from the same sample.
BiotechDigital HealthFemTech
Co-investorsAmboy Street VenturesDria VenturesBlue CollectiveCompany VenturesInnospark Ventures
Tidal Cyber develops tools and services that help enterprises adopt MITRE ATT&CK framework for threat-informed defense.
CybersecurityEnterprise Software
Rick Gordonin
Co-investorsAccess Venture PartnersBright Pixel CapitalDreamit VenturesGlasswing VenturesStoneMill VenturesTFX Capital+8 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.